Home >> Research Area >>Neuroscience>>Dopamine Receptor>> 7-Hydroxy-PIPAT maleate

7-Hydroxy-PIPAT maleate

D3 agonist (D3 > D2) CAS# 200722-46-9

7-Hydroxy-PIPAT maleate

Catalog No. BCC6760----Order now to get a substantial discount!

Product Name & Size Price Stock
7-Hydroxy-PIPAT maleate: 5mg $104 In Stock
7-Hydroxy-PIPAT maleate: 10mg Please Inquire In Stock
7-Hydroxy-PIPAT maleate: 20mg Please Inquire Please Inquire
7-Hydroxy-PIPAT maleate: 50mg Please Inquire Please Inquire
7-Hydroxy-PIPAT maleate: 100mg Please Inquire Please Inquire
7-Hydroxy-PIPAT maleate: 200mg Please Inquire Please Inquire
7-Hydroxy-PIPAT maleate: 500mg Please Inquire Please Inquire
7-Hydroxy-PIPAT maleate: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of 7-Hydroxy-PIPAT maleate

Number of papers citing our products

Chemical structure

7-Hydroxy-PIPAT maleate

3D structure

Chemical Properties of 7-Hydroxy-PIPAT maleate

Cas No. 200722-46-9 SDF Download SDF
PubChem ID 24978534 Appearance Powder
Formula C20H26INO5 M.Wt 487.33
Type of Compound N/A Storage Desiccate at -20°C
Synonyms 7-OH-PIPAT
Solubility Soluble to 50 mM in DMSO
Chemical Name (Z)-but-2-enedioic acid;7-[[(E)-3-iodoprop-2-enyl]-propylamino]-5,6,7,8-tetrahydronaphthalen-2-ol
SMILES CCCN(CC=CI)C1CCC2=C(C1)C=C(C=C2)O.C(=CC(=O)O)C(=O)O
Standard InChIKey IQRDHLSQXOATHD-HBRCEPSSSA-N
Standard InChI InChI=1S/C16H22INO.C4H4O4/c1-2-9-18(10-3-8-17)15-6-4-13-5-7-16(19)12-14(13)11-15;5-3(6)1-2-4(7)8/h3,5,7-8,12,15,19H,2,4,6,9-11H2,1H3;1-2H,(H,5,6)(H,7,8)/b8-3+;2-1-
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of 7-Hydroxy-PIPAT maleate

DescriptionThis ligand has uniquely high affinity and selectivity for the D3 receptor. 8-Hydroxy-PIPAT maleate also available.

7-Hydroxy-PIPAT maleate Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

7-Hydroxy-PIPAT maleate Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 7-Hydroxy-PIPAT maleate

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 2.052 mL 10.26 mL 20.52 mL 41.04 mL 51.2999 mL
5 mM 0.4104 mL 2.052 mL 4.104 mL 8.208 mL 10.26 mL
10 mM 0.2052 mL 1.026 mL 2.052 mL 4.104 mL 5.13 mL
50 mM 0.041 mL 0.2052 mL 0.4104 mL 0.8208 mL 1.026 mL
100 mM 0.0205 mL 0.1026 mL 0.2052 mL 0.4104 mL 0.513 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on 7-Hydroxy-PIPAT maleate

Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: Results at week 144.[Pubmed:28345157]

J Viral Hepat. 2017 Oct;24(10):877-884.

Reports on the efficacy and safety of long-term entecavir treatment in chronic hepatitis B (CHB) predominantly genotype B or C are insufficient. This study presents the efficacy and safety of entecavir maleate in Chinese CHB patients. Patients were randomly assigned to receive 48-week treatment with either 0.5 mg/day entecavir (group A) or 0.5 mg/day entecavir maleate (group B), and then all patients received treatment with 0.5 mg/day entecavir maleate from week 49. Two hundred and seventy-five patients with CHB (HBeAg-positive: 218) were analysed, predominantly (98.5%) with genotype B or C. Baseline characteristics were balanced. For the HBeAg-positive CHB patients, the mean HBV DNA level decreased similarly (A: by 6.36 log10 IU/mL vs B: by 6.31 log10 IU/mL) between groups at week 144. The percentages of patients who achieved undetectable HBV DNA were similar (A: 70.59% vs B: 66.67%) between groups. Similar HBeAg loss rates (A: 43.53% vs B: 40.23%; P>.05) and HBeAg seroconversion rates (A: 21.52% vs B: 21.18%) were achieved. For the HBeAg-negative CHB patients, similar reductions in HBV DNA levels from baseline (A: by 6.13 log10 IU/mL vs B: by 5.65 log10 IU/mL) and percentages of patients who achieved undetectable HBV DNA (A: 100% vs B: 100%) were achieved. The overall incidence of adverse events was comparable between groups. In conclusions, 48-week administration of entecavir maleate and entecavir showed similar efficacy and safety in Chinese patients with CHB. Long-term entecavir maleate treatment was effective and safe in CHB patients.

Determination of fluvoxamine maleate in human urine and human serum using alkaline KMnO4 -rhodamine B chemiluminescence.[Pubmed:28371383]

Luminescence. 2017 Sep;32(6):1077-1083.

The flow-injection chemiluminescence (FI-CL) behavior of a gold nanocluster (Au NC)-enhanced rhodamine B-KMnO4 system was studied under alkaline conditions for the first time. In the present study, the as-prepared bovine serum albumin-stabilized Au NCs showed excellent stability and reproducibility. The addition of trace levels of fluvoxamine maleate (Flu) led to an obvious decline in CL intensity in the rhodamine B-KMnO4 -Au NCs system, which could be used for quantitative detection of Flu. Under optimized conditions, the proposed CL system exhibited a favorable analytical performance for Flu determination in the range 2 to 100 mug ml(-1) . The detection limit for Flu measurement was 0.021 mug ml(-1) . Moreover, this newly developed system revealed outstanding selectivity for Flu detection when compared with a multitude of other species, such as the usual ions, uric acid and a section of hydroxy compounds. Additionally, CL spectra, UV-visible spectroscopes and fluorescence spectra were measured in order to determine the possible reaction mechanism. This approach could be used to detect Flu in human urine and human serum samples with the desired recoveries and could have promising application under physiological conditions.

[Chinese expert consensus on the use of topical timolol maleate treatment of infantile hemangiomas].[Pubmed:28275803]

Shanghai Kou Qiang Yi Xue. 2016 Dec;25(6):744-747.

Non-selective beta-blocker propranolol has been proved by FDA as the first-line agent for infantile hemangioma (IH) with dramatic response. To reduce the side effects caused by systemic administration of propranolol, timolol maleate treatment has been increasingly used as an alternative to systemic beta-blockers and watchful waiting for many IH patients in recent years. However, the appropriate indications, drug dosage, dosing regimen, time for initiation, optimal duration, monitoring for side effects still remains controversial. To standardize the use of topical timolol in treating IH, avoid overtreatment or under-treatment, as well as minimize complications, a Chinese expert consensus on the use of topical timolol treatment of IH has been approved and written by a multidisciplinary experts group based on an up-to-date literature review and repeated discussion, which can be used to reduce inappropriate variations in clinical practice and to promote the delivery of high quality, evidence-based health care for IH patients.

Evaluation of the effects on choroidal thickness of bimatoprost 0.03% versus a brinzolamide 1.0%/timolol maleate 0.5% fixed combination.[Pubmed:28376651]

Cutan Ocul Toxicol. 2017 Dec;36(4):397-403.

OBJECTIVE: To investigate the effects of two different medical treatment options on choroidal thickness (CT) in cases of open-angle glaucoma (OAG). METHODS: Sixty-seven eyes newly diagnosed with OAG and 52 healthy eyes constituting the control group were included in the study. Glaucomatous eyes were randomly divided into two subgroups; Group I was started on bimatoprost 0.03% and Group II on a brinzolamide 1.0%/timolol maleate 0.5% fixed combination (BTFC). Intraocular pressure (IOP), ocular pulse amplitude (OPA) and subfoveal CT measurements were performed in all eyes in the study before treatment and on weeks 2, 4 and 8 after treatment. RESULTS: Mean initial IOP values in groups I and II and the control group were 25.5 +/- 4.7, 25.1 +/- 5.2 and 16.1 +/- 2.9 mmHg, mean OPA values were 3.7 +/- 1, 3.6 +/- 1.4 and 2.4 +/- 0.6 mmHg and mean CT values were 269.4 +/- 83, 264.5 +/- 84.4 and 320.1 +/- 56.6 mum, respectively. Eight weeks after treatment, mean IOP values in Groups I and II and the control group were 18.3 +/- 2.6, 18.1 +/- 3.4 and 15.7 +/- 2.9 mmHg, mean OPA values were 2.9 +/- 1.2, 2.8 +/- 1.5 and 2.3 +/- 0.8 mmHg and mean CT values were 290.2 +/- 87.3, 271.8 +/- 82.5 and 319.3 +/- 56.8 mum, respectively. No significant difference was determined in terms of the decrease in IOP and OPA obtained after treatment in Group I and Group II. However, a significant difference was observed between the two groups in terms of choroidal thickening after treatment. CONCLUSION: The use of topical ocular hypotensive medication in eyes with OAG results in an increase in CT. This increase is relatively greater with bimatoprost 0.03% therapy compared to BTFC.

Synthesis and optical resolution of (R)- and (S)-trans-7-Hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin: a new D3 dopamine receptor ligand.[Pubmed:8277513]

J Med Chem. 1993 Dec 24;36(26):4308-12.

An improved method for synthesis and resolution of (R,S)-trans-7-hydroxy-2-[N-propyl-N-(3'-iodo-2'-propenyl)amino]tetralin (trans-7-OH-PlPAT,5), a new D3 dopamine receptor ligand, was reported. Both isomers, (R)-(+)- and (S)-(-)-5, were prepared and characterized. HPLC retention times obtained on a chiral column for these isomers were consistent with those observed for [125I]-(R)-(+)- and (S)-(-)-5. Direct radioiodination of an optically resolved tin precursor, (R)-(+)-7, yielded the desired [125I](R)-(+)-5, which is a simpler method for synthesis of this ligand. Binding studies with membrane preparations containing D3 dopamine receptors expressed in Spodoptera frugiperda (Sf9) cells also suggested that the [125I](R)-(+)-5 is the active isomer (Kd = 0.05 nM). The schemes described may provide an efficient way for synthesizing a large quantity of this new D3 dopamine receptor ligand for in vivo behavior studies.

In vitro binding of a novel dopamine D3 receptor ligand: [125I]trans-7-OH-PIPAT-A.[Pubmed:8519278]

Eur J Pharmacol. 1993 Apr 22;235(1):165-6.

An iodinated dopamine D3 receptor ligand, [125I]trans-7-OH-PIPAT-A-trans-7-hydroxy-2-(N-n-propyl-N-3'-iodo-2 '- propenyl)aminotetralin, was developed. This ligand demonstrated unique high affinity and selectivity toward the dopamine D3 receptor; Kd = 0.48 nM and Bmax = 240 fmol/mg of protein in rat striatal membrane homogenates.

Keywords:

7-Hydroxy-PIPAT maleate,200722-46-9,7-OH-PIPAT,Natural Products,Dopamine Receptor, buy 7-Hydroxy-PIPAT maleate , 7-Hydroxy-PIPAT maleate supplier , purchase 7-Hydroxy-PIPAT maleate , 7-Hydroxy-PIPAT maleate cost , 7-Hydroxy-PIPAT maleate manufacturer , order 7-Hydroxy-PIPAT maleate , high purity 7-Hydroxy-PIPAT maleate

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: